RGLS — Regulus Therapeutics Share News
0.000.00%
Last trade - 00:00- $563.57m
- $498.20m
Regulus Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Regulus Therapeutics Announces Positive Topline Data
Brief: Regulus Therapeutics Announces Promotion of Rekha Garg to Chief Medical Officer
Regulus Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Brief: Regulus Therapeutics Inc Entered Into A Securities Purchase Agreement On March 11
U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners
U.S. STOCKS ON THE MOVE-Li-Cycle Holdings, Priority Technology, 3M
U.S. STOCKS ON THE MOVE-Madrigal Pharmaceuticals, Coinbase, Fractyl
Regulus Therapeutics doubles as kidney disease therapy shows promise in trial
U.S. STOCKS ON THE MOVE-Carvana, ADM, Oracle
Brief: Regulus Therapeutics Announces Oversubscribed $100 Mln Private Placement
Brief: Regulus Announces Positive Data From The Second Cohort In Phase 1B Clinical Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
Regulus rises as kidney disease therapy shows promise in early-stage trial
Brief: Regulus Therapeutics Announces Completion Of Enrollment In Third Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429
Brief: Regulus Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Regulus Therapeutics Announces First Patient Dosed In Third Cohort